Brendon Yee, PhD, professor and respiratory and sleep physician, Woolcock Institute of Medical Research, discusses the success of ALKS 2680, an investigational oral selective orexin 2 receptor agonist ...
The orexin/hypocretin system, first identified in 1998, is now recognized as a central regulator of energy balance, sleep–wake states, and arousal ...
Takeda’s orexin receptor 2 agonist oveporexton succeeded in two phase III trials, setting up a first FDA filing for the small molecule for the treatment of narcolepsy type 1. Other companies including ...
NLS Pharmaceutics (NLSP) provided insights into the preclinical program evaluating its dual orexin receptor agonist platform. AEX-41 and AEX-2, two first-in-class non-sulfonamide DOXAs, are designed ...
ZÜRICH, SWITZERLAND / ACCESSWIRE / December 3, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) (NLS), a biopharmaceutical company, is pleased to share preclinical data demonstrating the ...
– Alixorexton is the First Oral Orexin 2 Receptor Agonist to Demonstrate Efficacy in a Large Phase 2 Study in Patients With Narcolepsy Type 2, Supporting Advancement to Phase 3 – – Alixorexton Met the ...
It’s not often that a pharmaceutical executive discusses a competitor’s success. Alkermes Chief Operating Officer Blair Jackson not only talks about it openly, he cheers it. Alkermes’s scope in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results